Product image of Ledaga (Chlormethine) supplied by GNH India

Ledaga

Active Ingredient:
Chlormethine
Origin:
EU

Ledaga (Chlormethine)

Chlormethine, the active ingredient in Ledaga, is an alkylating agent presented as a topical formulation for cutaneous (topical) use. It is employed to treat mycosis fungoides, a form of cutaneous T‑cell lymphoma, in adult patients requiring skin‑directed and localized therapy.

GNH India supplies Ledaga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring reliable quality, regulatory compliance and timely delivery across multiple markets, and supporting clinical research initiatives in dermatologic oncology.

Manufacturer / TM Owner

Helsinn Birex Pharmaceuticals Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ledaga (chlormethine) is used in the management of cutaneous T‑cell lymphoma, specifically mycosis fungoides.
  • Mycosis fungoides (early‑stage): local disease control and reduction of skin lesions.
  • Mycosis fungoides (advanced‑stage): palliative improvement of skin‑related symptoms.
  • Cutaneous T‑cell lymphoma refractory to other therapies: provides an alternative topical chemotherapy option.

How It Works

  • Chlormethine acts as an alkylating agent that forms covalent bonds with DNA bases, creating interstrand cross‑links that block DNA replication and transcription. The resulting DNA damage triggers apoptosis of rapidly proliferating malignant T‑cells in the skin, thereby reducing tumor burden in cutaneous T‑cell lymphoma.

Side Effects

Topical chlormethine can cause a range of skin‑related reactions, from mild irritation to more serious complications.

Common Side Effects

  • Erythema or redness at the application site.
  • Pruritus (itching) or burning sensation.
  • Dryness or scaling of the skin.
  • Hyperpigmentation of treated areas.
  • Localized edema or swelling.
  • Mild pain or tenderness.

Serious or Rare Side Effects

  • Severe allergic reaction (e.g., angio‑edema, anaphylaxis).
  • Ulceration or necrosis of the skin.
  • Secondary bacterial or fungal infection of the lesion.
  • Systemic absorption leading to bone‑marrow suppression (rare).
  • Development of secondary skin malignancies.
  • Persistent dermatitis unresponsive to conventional therapy.

Precautions & Warnings

  • Before initiating therapy with Ledaga, clinicians should evaluate the patient’s overall skin condition and medical history.
  • Assess skin integrity: ensure lesions are not ulcerated or infected before application.
  • Avoid application on broken or inflamed skin: limit use to intact lesions.
  • Use protective gloves: wear gloves during application to prevent accidental exposure.
  • Monitor for signs of infection: watch for increasing redness, pus, or fever.
  • Avoid use in patients with known hypersensitivity to chlormethine or related compounds.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Chlormethine may interact with other topical or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid)

  • Concurrent use of other topical alkylating agents: risk of cumulative toxicity.
  • Systemic chemotherapy (e.g., cyclophosphamide): may increase systemic exposure and bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

  • Topical corticosteroids: may reduce chlormethine efficacy.
  • UV phototherapy (PUVA, UVB): can heighten skin irritation.
  • Other skin irritants (e.g., retinoids, salicylic acid): may exacerbate local reactions.
  • Immunosuppressive drugs: could increase risk of infection at the application site.

Frequently Asked Questions

Ledaga contains chlormethine, a topical alkylating agent indicated for the treatment of mycosis fungoides, the most common form of cutaneous T‑cell lymphoma. It is applied directly to skin lesions to reduce tumor burden and control disease progression.

Chlormethine alkylates DNA within malignant T‑cells in the skin, forming cross‑links that block DNA replication and transcription. This DNA damage triggers programmed cell death (apoptosis), leading to reduction of the lymphoma cells in the treated area.

The prescribed dose of Ledaga is determined by the treating physician based on the extent and stage of the disease, the patient’s skin condition, and local prescribing guidelines. Dosing regimens are individualized and should not be altered without medical advice.

Safety data for chlormethine in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Ledaga, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ledaga offers a topical chemotherapy option that directly targets skin lesions, whereas systemic agents treat disease throughout the body. Compared with phototherapy, Ledaga can be used on localized plaques and patches, but may cause more local skin irritation. Choice of therapy depends on disease stage, patient preference and overall health.

Ledaga should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight. Ensure the container is tightly closed when not in use to maintain stability and potency.

Ledaga is applied topically to the affected skin areas as directed by the prescribing clinician. The recommended amount and frequency depend on lesion size and severity. Hands should be washed before and after application, and protective gloves are advised to avoid accidental exposure.

Serious risks include severe allergic reactions, ulceration or necrosis of the skin, secondary infections, and, rarely, systemic absorption leading to bone‑marrow suppression. Patients should be monitored for signs of these events, and treatment should be discontinued if severe adverse reactions occur.

Ledaga should not be used in patients with known hypersensitivity to chlormethine or other nitrogen‑mustard compounds, on severely broken or infected skin, or in individuals where the risk of systemic toxicity outweighs the potential benefit. The prescribing clinician will assess suitability for each patient.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Chlormethine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT